We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Read MoreHide Full Article
Key Takeaways
Keytruda drove over half of Merck's pharma revenues in the first nine months of 2025.
Keytruda sales rose 8% year over year in the third quarter but were weaker than expected.
FDA nod to Keytruda Qlex extends patent protection beyond 2028 and aids potential long-term growth.
Merck’s (MRK - Free Report) strong position in the oncology market is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor contributes over half of the company’s pharmaceutical revenues.
Keytruda, approved for different types of cancer indications, has played an instrumental role in driving Merck’s steady revenue growth in recent years.
Keytruda generated sales of $23.30 billion in the first nine months of 2025, out of which $8.14 billion was recorded during the third quarter. Though Keytruda sales increased 8% year over year during the third quarter of 2025, they were weaker than expected.
Keytruda sales missed the Zacks Consensus Estimate of $8.40 billion in the third quarter.
Management defended that Keytruda's soft sales in the third quarter were due to unfavorable channel movements and not due to a drop in underlying demand.
Keytruda sales are gaining rapid uptake across earlier-stage indications and continued strong momentum in metastatic indications. The company expects continued growth from Keytruda, particularly in early lung cancer.
In 2026, the company expects Keytruda to grow and expand into new indications and markets globally continuously, as the FDA decision for ovarian cancer, as well as other cancer indications, draws closer. Keytruda is not approved to treat ovarian cancer.
MRK Seeks Keytruda's Long-Term Growth Amid Upcoming Patent Loss
With Keytruda set to face patent loss in 2028, Merck is working on different strategies to drive its long-term growth.
The FDA recently approved the subcutaneous (SC) formulation of Keytruda, known as Keytruda Qlex, which improves patient convenience. With Keytruda's intravenous (IV) formulation losing exclusivity in 2028, Keytruda Qlex’s own patents extend protection beyond that date, which can help offset the impact of the IV version’s patent expiry.
Merck is also advancing innovative immuno-oncology combinations, such as pairing Keytruda with LAG3 and CTLA-4 inhibitors.
In partnership with Moderna (MRNA - Free Report) , Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in combination with Keytruda for patients with certain types of melanoma and non-small cell lung cancer (NSCLC).
Merck and Moderna are conducting pivotal phase III studies on V940, in combination with Keytruda, for earlier-stage and adjuvant NSCLC and adjuvant melanoma.
While Keytruda continues to drive Merck’s growth, the company’s heavy dependence on the drug remains a concern.
Also, competitive pressure might increase for Keytruda in the near future from dual PD-1/VEGF inhibitors like Summit Therapeutics’ (SMMT - Free Report) ivonescimab that inhibit both the PD-1 pathway and the VEGF pathway at once.
Summit believes ivonescimab has the potential to replace Keytruda as the next standard of care across multiple NSCLC settings. Ivonescimab previously outperformed Keytruda in a phase III study in patients with locally advanced or metastatic NSCLC.
Though Keytruda IV is set to face loss of exclusivity in 2028, its sales are expected to stay strong until then. Recent approvals and the expected launch of many additional indications, including in earlier lines of therapy, are likely to propel Keytruda’s sales in 2026 and beyond.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have declined 13.2% against the industry’s rise of 6.4%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 9.28 forward earnings, lower than 15.57 for the industry and its 5-year mean of 12.58.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has inched up from $8.94 to $8.95, while the same for 2026 has decreased from $9.54 to $9.35 over the past 30 days.
Image: Bigstock
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Key Takeaways
Merck’s (MRK - Free Report) strong position in the oncology market is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor contributes over half of the company’s pharmaceutical revenues.
Keytruda, approved for different types of cancer indications, has played an instrumental role in driving Merck’s steady revenue growth in recent years.
Keytruda generated sales of $23.30 billion in the first nine months of 2025, out of which $8.14 billion was recorded during the third quarter. Though Keytruda sales increased 8% year over year during the third quarter of 2025, they were weaker than expected.
Keytruda sales missed the Zacks Consensus Estimate of $8.40 billion in the third quarter.
Management defended that Keytruda's soft sales in the third quarter were due to unfavorable channel movements and not due to a drop in underlying demand.
Keytruda sales are gaining rapid uptake across earlier-stage indications and continued strong momentum in metastatic indications. The company expects continued growth from Keytruda, particularly in early lung cancer.
In 2026, the company expects Keytruda to grow and expand into new indications and markets globally continuously, as the FDA decision for ovarian cancer, as well as other cancer indications, draws closer. Keytruda is not approved to treat ovarian cancer.
MRK Seeks Keytruda's Long-Term Growth Amid Upcoming Patent Loss
With Keytruda set to face patent loss in 2028, Merck is working on different strategies to drive its long-term growth.
The FDA recently approved the subcutaneous (SC) formulation of Keytruda, known as Keytruda Qlex, which improves patient convenience. With Keytruda's intravenous (IV) formulation losing exclusivity in 2028, Keytruda Qlex’s own patents extend protection beyond that date, which can help offset the impact of the IV version’s patent expiry.
Merck is also advancing innovative immuno-oncology combinations, such as pairing Keytruda with LAG3 and CTLA-4 inhibitors.
In partnership with Moderna (MRNA - Free Report) , Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in combination with Keytruda for patients with certain types of melanoma and non-small cell lung cancer (NSCLC).
Merck and Moderna are conducting pivotal phase III studies on V940, in combination with Keytruda, for earlier-stage and adjuvant NSCLC and adjuvant melanoma.
While Keytruda continues to drive Merck’s growth, the company’s heavy dependence on the drug remains a concern.
Also, competitive pressure might increase for Keytruda in the near future from dual PD-1/VEGF inhibitors like Summit Therapeutics’ (SMMT - Free Report) ivonescimab that inhibit both the PD-1 pathway and the VEGF pathway at once.
Summit believes ivonescimab has the potential to replace Keytruda as the next standard of care across multiple NSCLC settings. Ivonescimab previously outperformed Keytruda in a phase III study in patients with locally advanced or metastatic NSCLC.
Though Keytruda IV is set to face loss of exclusivity in 2028, its sales are expected to stay strong until then. Recent approvals and the expected launch of many additional indications, including in earlier lines of therapy, are likely to propel Keytruda’s sales in 2026 and beyond.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have declined 13.2% against the industry’s rise of 6.4%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 9.28 forward earnings, lower than 15.57 for the industry and its 5-year mean of 12.58.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has inched up from $8.94 to $8.95, while the same for 2026 has decreased from $9.54 to $9.35 over the past 30 days.
Image Source: Zacks Investment Research
MRK's Zacks Rank
Merck currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.